Immunotherapy Combo Flops in Metastatic NSCLC
(MedPage Today) -- Durvalumab plus tremelimumab failed to improve survival versus chemotherapy
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Chemotherapy | Hematology | Immunotherapy | Non-Small Cell Lung Cancer